Pieris Pharmaceuticals Inc. (PIRS) is priced at $3.52 after the most recent trading session. At the very opening of the session, the stock price was $3.781 and reached a high price of $3.781, prior to closing the session it reached the value of $3.69. The stock touched a low price of $3.46.
Recently in News on June 25, 2021, Pieris Pharmaceuticals Announces Inhaled CTGF Inhibitor PRS-220 for Idiopathic Pulmonary Fibrosis and 17 Million Dollar Grant From Bavarian Government To Accelerate Program Development for Post-COVID-19 Pulmonary Fibrosis. PRS-220, an oral inhaled Anticalin protein targeting CTGF, a fully proprietary drug candidate for respiratory disease, is being developed as a local treatment for idiopathic pulmonary fibrosis. You can read further details here
Pieris Pharmaceuticals Inc. had a pretty favorable run when it comes to the market performance. The 1-year high price for the company’s stock is recorded $5.09 on 05/26/21, with the lowest value was $1.70 for the same time period, recorded on 05/05/21.
Pieris Pharmaceuticals Inc. (PIRS) full year performance was 7.32%
Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stock’s existing status and the future performance. Presently, Pieris Pharmaceuticals Inc. shares are logging -30.84% during the 52-week period from high price, and 107.06% higher than the lowest price point for the same timeframe. The stock’s price range for the 52-week period managed to maintain the performance between $1.70 and $5.09.
The company’s shares, operating in the sector of Healthcare managed to top a trading volume set approximately around 4009220 for the day, which was evidently lower, when compared to the average daily volumes of the shares.
When it comes to the year-to-date metrics, the Pieris Pharmaceuticals Inc. (PIRS) recorded performance in the market was 40.80%, having the revenues showcasing 52.38% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 226.65M, as it employees total of 111 workers.
Market experts do have their say about Pieris Pharmaceuticals Inc. (PIRS)
During the last month, 4 analysts gave the Pieris Pharmaceuticals Inc. a BUY rating, 0 of the polled analysts branded the stock as an OVERWEIGHT, 0 analysts were recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 0 of the polled analysts provided SELL rating.
According to the data provided on Barchart.com, the moving average of the company in the 100-day period was set at 2.83, with a change in the price was noted +0.72. In a similar fashion, Pieris Pharmaceuticals Inc. posted a movement of +25.71% for the period of last 100 days, recording 7,257,844 in trading volumes.
Total Debt to Equity Ratio (D/E) can also provide valuable insight into the company’s financial health and market status. The debt to equity ratio can be calculated by dividing the present total liabilities of a company by shareholders’ equity. Debt to Equity thus makes a valuable metrics that describes the debt, company is using in order to support assets, correlating with the value of shareholders’ equity The total Debt to Equity ratio for PIRS is recording 0.00 at the time of this writing. In addition, long term Debt to Equity ratio is set at 0.00.
Technical breakdown of Pieris Pharmaceuticals Inc. (PIRS)
Raw Stochastic average of Pieris Pharmaceuticals Inc. in the period of last 50 days is set at 52.99%. The result represents improvement in oppose to Raw Stochastic average for the period of the last 20 days, recording 10.32%. In the last 20 days, the company’s Stochastic %K was 14.58% and its Stochastic %D was recorded 14.90%.
Bearing in mind the latest performance of Pieris Pharmaceuticals Inc., several moving trends are noted. Year-to-date Price performance of the company’s stock appears to be pessimistic, given the fact the metric is recording 40.80%. Additionally, trading for the stock in the period of the last six months notably improved by 31.84%, alongside a boost of 7.32% for the period of the last 12 months. The shares increased approximately by -1.12% in the 7-day charts and went down by -0.28% in the period of the last 30 days. Common stock shares were driven by 52.38% during last recorded quarter.